title: Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
abstract: BACKGROUND
  Administration of recombinant interleukin-2 (rIL-2) can mediate tumor regression in patients with metastatic melanoma and renal cell carcinoma. In response to recent FDA approval of high dose rIL-2 for use in renal cell carcinoma, the authors recent experience with the cardiopulmonary toxicity associated with high dose IL-2 therapy is reviewed.
  
  
  METHODS
  The treatment courses of all patients receiving high dose intravenous bolus rIL-2 from January, 1988, until December, 1992, were evaluated for cardiopulmonary toxicity.
  
  
  RESULTS
  One hundred ninety-nine patients received 310 courses of treatment. There were no treatment-related deaths. Respiratory distress occurred in 3.2% of the courses, requiring intubation in one patient. Three obtunded patients were endotracheally intubated for airway control. Arrhythmias occurred in 6% of the courses (18 patients) with hypotension developing in two of the 199 patients as a result. Eleven of these patients were retreated and recurrent atrial fibrillation developed in two. One episode of significant ventricular tachycardia was noted. Hypotension occurred in 53% of courses; no patients developed hypotension unresponsive to vasopressors. There were no myocardial infarctions; however, 2.5% of patients experienced elevated creatine phosphokinase levels associated with elevated MB isoenzymes attributed to cardiac toxicity. Only one of these patients developed symptoms. Response rates of 19.6% and 15.7% were noted in patients with renal cell carcinoma and melanoma, respectively. Hypotension requiring vasopressors was associated with a significantly improved rate of response in patients with melanoma compared with patients not requiring vasopressors (23.2% vs. 6.5%, P2 = 0.037).
  
  
  CONCLUSIONS
  Although high dose intravenous rIL-2 therapy can be associated with cardiopulmonary toxicity, toxic side effects generally are not severe and are rapidly reversible.
authors.affiliation: Surgery Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
authors.forename: R L
authors.initials: RL
authors.lastname: White
authors.forename: D J
authors.initials: DJ
authors.lastname: Schwartzentruber
authors.forename: A
authors.initials: A
authors.lastname: Guleria
authors.forename: M P
authors.initials: MP
authors.lastname: MacFarlane
authors.forename: D E
authors.initials: DE
authors.lastname: White
authors.forename: E
authors.initials: E
authors.lastname: Tucker
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D009202:Cardiomyopathies / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002648:Child; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012131:Respiratory Insufficiency / Q000139:chemically induced*
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins